Drug intelligence / Profile preview

influenza virus vaccine, purified chick embryo cell culture

Development stage: Approved
Lead developer: CSL Seqirus
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

This refers to a type of influenza vaccine produced by cultivating influenza viruses in purified chick embryo cell cultures. The viruses are then harvested, inactivated, and purified to create a vaccine designed to stimulate the immune system and provide protection against influenza infection. While cell culture technology is used for some influenza vaccines, the most common cell lines for influenza vaccine production are mammalian (e.g., MDCK cells), and the term "purified chick embryo cell vaccine" (PCECV) is primarily associated with rabies vaccines.

Beyond the preview

Go deeper on influenza virus vaccine, purified chick embryo cell culture.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza virus vaccine, purified chick embryo cell culture.

Explore the full profile